These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1012 related articles for article (PubMed ID: 33979771)

  • 1. Can coronavirus disease 2019 (COVID-19) trigger exacerbation of multiple sclerosis? A retrospective study.
    Barzegar M; Vaheb S; Mirmosayyeb O; Afshari-Safavi A; Nehzat N; Shaygannejad V
    Mult Scler Relat Disord; 2021 Jul; 52():102947. PubMed ID: 33979771
    [TBL] [Abstract][Full Text] [Related]  

  • 2. COVID-19 and the Risk of Relapse in Multiple Sclerosis Patients: A Fight with No Bystander Effect?
    Etemadifar M; Sedaghat N; Aghababaee A; Kargaran PK; Maracy MR; Ganjalikhani-Hakemi M; Rayani M; Abhari AP; Khorvash R; Salari M; Nouri H
    Mult Scler Relat Disord; 2021 Jun; 51():102915. PubMed ID: 33799284
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Can coronavirus disease 2019 (COVID-19) trigger exacerbation of multiple sclerosis? A retrospective study.
    Sedaghat N
    Mult Scler Relat Disord; 2021 Aug; 53():103054. PubMed ID: 34102605
    [No Abstract]   [Full Text] [Related]  

  • 4. Association between relapses, stress, and depression in people with multiple sclerosis during the COVID-19 pandemic.
    Sparaco M; Miele G; Lavorgna L; Abbadessa G; Bonavita S
    Neurol Sci; 2022 May; 43(5):2935-2942. PubMed ID: 35092543
    [TBL] [Abstract][Full Text] [Related]  

  • 5. SARS-CoV-2 triggered relapse of multiple sclerosis.
    Finsterer J
    Clin Neurol Neurosurg; 2022 Apr; 215():107210. PubMed ID: 35305393
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Does COVID-19 increase the long-term relapsing-remitting multiple sclerosis clinical activity? A cohort study.
    Etemadifar M; Abhari AP; Nouri H; Salari M; Maleki S; Amin A; Sedaghat N
    BMC Neurol; 2022 Feb; 22(1):64. PubMed ID: 35193507
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Natalizumab administration in multiple sclerosis patients during active SARS-CoV-2 infection: a case series.
    Chisari CG; Toscano S; Arena S; Finocchiaro C; Montineri A; Patti F
    BMC Neurol; 2021 Nov; 21(1):462. PubMed ID: 34839814
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The natural history of multiple sclerosis: a geographically based study 10: relapses and long-term disability.
    Scalfari A; Neuhaus A; Degenhardt A; Rice GP; Muraro PA; Daumer M; Ebers GC
    Brain; 2010 Jul; 133(Pt 7):1914-29. PubMed ID: 20534650
    [TBL] [Abstract][Full Text] [Related]  

  • 9. SARS-CoV-2 infection and seroprevalence in patients with multiple sclerosis.
    Piñar Morales R; Ramírez Rivas MA; Barrero Hernández FJ
    Neurologia (Engl Ed); 2021; 36(9):698-703. PubMed ID: 34103271
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Progression is independent of relapse activity in early multiple sclerosis: a real-life cohort study.
    Portaccio E; Bellinvia A; Fonderico M; Pastò L; Razzolini L; Totaro R; Spitaleri D; Lugaresi A; Cocco E; Onofrj M; Di Palma F; Patti F; Maimone D; Valentino P; Confalonieri P; Protti A; Sola P; Lus G; Maniscalco GT; Brescia Morra V; Salemi G; Granella F; Pesci I; Bergamaschi R; Aguglia U; Vianello M; Simone M; Lepore V; Iaffaldano P; Filippi M; Trojano M; Amato MP
    Brain; 2022 Aug; 145(8):2796-2805. PubMed ID: 35325059
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Clinical course and outcome of SARS-CoV-2 infection in multiple sclerosis patients treated with disease-modifying therapies - the Polish experience.
    Czarnowska A; Brola W; Zajkowska O; Rusek S; Adamczyk-Sowa M; Kubicka-Bączyk K; Kalinowska-Łyszczarz A; Kania K; Słowik A; Wnuk M; Marona M; Podlecka-Piętowska A; Nojszewska M; Zakrzewska-Pniewska B; Jasińska E; Gołuch K; Lech B; Noga M; Perenc A; Popiel M; Lasek-Bal A; Puz P; Maciejowska K; Kucharska-Lipowska M; Lipowski M; Kapica-Topczewska K; Chorąży M; Tarasiuk J; Kochanowicz J; Kulikowska J; Wawrzyniak S; Niezgodzińska-Maciejek A; Pokryszko-Dragan A; Gruszka E; Budrewicz S; Białek M; Kurkowska-Jastrzębska I; Kurowska K; Stępień A; Włodek A; Ptasznik V; Pawełczyk M; Sobolewski P; Lejmel H; Strzalińska K; Maciejowski M; Tutaj A; Zwiernik J; Litwin A; Lewańczyk B; Paprocka I; Zwiernik B; Pawlos A; Borysowicz A; Narożnik A; Michałowska A; Nosek K; Fudala M; Milewska-Jędrzejczak M; Kułakowska A; Bartosik-Psujek H
    Neurol Neurochir Pol; 2021; 55(2):212-222. PubMed ID: 33856686
    [TBL] [Abstract][Full Text] [Related]  

  • 12. ¿ Can COVID-19 exacerbate multiple sclerosis symptoms? A case series analysis.
    Michelena G; Casas M; Eizaguirre MB; Pita MC; Cohen L; Alonso R; Garcea O; Silva BA
    Mult Scler Relat Disord; 2022 Jan; 57():103368. PubMed ID: 35158474
    [TBL] [Abstract][Full Text] [Related]  

  • 13. COVID-19 in Argentine teriflunomide-treated multiple sclerosis patients: First national case series.
    Luetic G; Menichini ML; Burgos M; Alonso R; Carnero Contentti E; Carrá A; Deri N; Steinberg J; Rojas JI;
    Mult Scler Relat Disord; 2021 Aug; 53():103049. PubMed ID: 34130197
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The association of upper respiratory infections with neuro-radiological course and attack rate of multiple sclerosis: Results from a large prospective cohort.
    Ghasemi M; Farazandeh D; Amini B; Sedaghat M; Najafi A; Khayatzadeh Kakhki S; Torabi P; Jafarimehrabady N; Bitaraf A; Shariati H; Gholampour G; Kazemi S; Naser Moghadasi A; Vajihinejad M
    Mult Scler J Exp Transl Clin; 2023; 9(3):20552173231196992. PubMed ID: 37767104
    [TBL] [Abstract][Full Text] [Related]  

  • 15. COVID-19 is associated with new symptoms of multiple sclerosis that are prevented by disease modifying therapies.
    Garjani A; Middleton RM; Hunter R; Tuite-Dalton KA; Coles A; Dobson R; Duddy M; Hughes S; Pearson OR; Rog D; Tallantyre EC; das Nair R; Nicholas R; Evangelou N
    Mult Scler Relat Disord; 2021 Jul; 52():102939. PubMed ID: 34010764
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Risk of Getting COVID-19 in People With Multiple Sclerosis: A Case-Control Study.
    Iaffaldano P; Lucisano G; Manni A; Paolicelli D; Patti F; Capobianco M; Brescia Morra V; Sola P; Pesci I; Lus G; De Luca G; Lugaresi A; Cavalla P; Montepietra S; Maniscalco GT; Granella F; Ragonese P; Vianello M; Brambilla L; Totaro R; Toscano S; Malucchi S; Petracca M; Moiola L; Ferraro D; Lepore V; Mosconi P; Ponzio M; Tedeschi G; Comi G; Battaglia MA; Filippi M; Amato MP; Trojano M;
    Neurol Neuroimmunol Neuroinflamm; 2022 Mar; 9(2):. PubMed ID: 35046084
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The disease course of multiple sclerosis before and during COVID-19 pandemic: A retrospective five-year study.
    Babtain F; Bajafar A; Nazmi O; Badawi M; Basndwah A; Bushnag A; Cupler E; Hassan A
    Mult Scler Relat Disord; 2022 Sep; 65():103985. PubMed ID: 35759904
    [TBL] [Abstract][Full Text] [Related]  

  • 18. COVID-19 in cladribine-treated relapsing-remitting multiple sclerosis patients: a monocentric experience.
    Preziosa P; Rocca MA; Nozzolillo A; Moiola L; Filippi M
    J Neurol; 2021 Aug; 268(8):2697-2699. PubMed ID: 33216223
    [No Abstract]   [Full Text] [Related]  

  • 19. B-cell depleting therapies may affect susceptibility to acute respiratory illness among patients with multiple sclerosis during the early COVID-19 epidemic in Iran.
    Safavi F; Nourbakhsh B; Azimi AR
    Mult Scler Relat Disord; 2020 Aug; 43():102195. PubMed ID: 32460086
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Assessing disability and relapses in multiple sclerosis on tele-neurology.
    Moccia M; Lanzillo R; Brescia Morra V; Bonavita S; Tedeschi G; Leocani L; Lavorgna L;
    Neurol Sci; 2020 Jun; 41(6):1369-1371. PubMed ID: 32440979
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 51.